PDCD1 and renal cell carcinoma: In a first-in-human phase I study, ciforadenant was given as a monotherapy or in combination with anti-PD-L1 atezolizumab in an advanced RCC cohort of 68 patients, of which 72% were resistant or refractory to prior anti-PD1/PD-L1 therapy [35].